Sci-Tech News Today
SEE OTHER BRANDS

The latest news on science and technology

Sci-Tech News Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech News Today.

Press releases published on June 6, 2025

PanBrain Technology, with EEG and tDCS Technologies, Wins Dual Honors in China

PanBrain Technology, with EEG and tDCS Technologies, Wins Dual Honors in China

PanBrain Technology has been awarded as “National High-tech Enterprise” and “Specialized, Refined, Distinctive and Innovative” SME in Shenzhen CA, UNITED STATES, June 6, 2025 /⁨EINPresswire.com⁩/ -- PanBrain Technology Co., Ltd., a leading innovator in …

BlackRock® Canada Announces Changes to the iShares Jantzi Social Index ETF

BlackRock® Canada Announces Changes to the iShares Jantzi Social Index ETF

TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”) (NYSE: BLK), is announcing that iShares Jantzi Social Index ETF (the “iShares …

BlackRock® Canada annonce des modifications au iShares Jantzi Social Index ETF

BlackRock® Canada annonce des modifications au iShares Jantzi Social Index ETF

TORONTO, 06 juin 2025 (GLOBE NEWSWIRE) -- Gestion d’actifs BlackRock Canada Limitée (« BlackRock Canada »), filiale en propriété exclusive indirecte de BlackRock, Inc. (« BlackRock ») (NYSE : BLK), annonce que le iShares Jantzi Social Index ETF (le « FNB  …

Digi Power X Announces Grant of Stock Options

Digi Power X Announces Grant of Stock Options

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“ …

The Essential Photomask Blanks Powering Semiconductors and Driving the Digital World

The Essential Photomask Blanks Powering Semiconductors and Driving the Digital World

SINGAPORE, June 6, 2025 /⁨EINPresswire.com⁩/ -- HOYA Electronics, a global leader in photomask blanks, today announced the release of a short video production as part of the “Economy 4.0” documentary series hosted on CBS News. The film delves into the …

Talisker Closes Non-Brokered Private Placement for Gross Proceeds of Approximately $14 Million

Talisker Closes Non-Brokered Private Placement for Gross Proceeds of Approximately $14 Million

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) is pleased to announce that it has …

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today …

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …

Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million

Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million

VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) --  Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered …

RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress

RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress

MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design …

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report …

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing …

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly …

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology …

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an …

OBI Pharma geht AWK-Zusammenarbeit mit TegMine Therapeutics bei der Nutzung von GlycOBI® und TegMiner™ Enabling Technologies ein

OBI Pharma geht AWK-Zusammenarbeit mit TegMine Therapeutics bei der Nutzung von GlycOBI® und TegMiner™ Enabling Technologies ein

TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), ein globales, im klinischen Stadium tätiges Onkologieunternehmen, das auf die Entwicklung neuartiger Krebstherapien wie Antikörper-Wirkstoff-Konjugate (AWK) (4174. TWO) spezialisiert …

Collaboration entre OBI Pharma et TegMine Therapeutics autour des ADC, reposant sur les technologies habilitantes GlycOBI® et TegMiner™

Collaboration entre OBI Pharma et TegMine Therapeutics autour des ADC, reposant sur les technologies habilitantes GlycOBI® et TegMiner™

TAIPEI, Taïwan, 06 juin 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), une société internationale d’oncologie au stade clinique, spécialisée dans le développement de nouvelles thérapies contre le cancer, telles que les conjugués anticorps-médicaments ( …

First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients

First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients

Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) -- First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service